DiaMedica Therapeutics (NASDAQ:DMAC) Major Shareholder Jan Stahlberg Buys 73,099 Shares of Stock

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) major shareholder Jan Stahlberg purchased 73,099 shares of the firm’s stock in a transaction on Tuesday, November 25th. The shares were acquired at an average cost of $8.57 per share, with a total value of $626,458.43. Following the completion of the acquisition, the insider directly owned 8,825,742 shares in the company, valued at $75,636,608.94. The trade was a 0.84% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Jan Stahlberg also recently made the following trade(s):

• On Monday, November 24th, Jan Stahlberg bought 40,253 shares of DiaMedica Therapeutics stock. The shares were acquired at an average cost of $7.89 per share, for a total transaction of $317,596.17.
• On Friday, November 21st, Jan Stahlberg bought 208,872 shares of DiaMedica Therapeutics stock. The shares were acquired at an average price of $7.41 per share, with a total value of $1,547,741.52.
• On Thursday, November 20th, Jan Stahlberg purchased 128,426 shares of DiaMedica Therapeutics stock. The stock was bought at an average price of $7.41 per share, for a total transaction of $951,636.66.
• On Wednesday, November 19th, Jan Stahlberg acquired 240,352 shares of DiaMedica Therapeutics stock. The shares were bought at an average cost of $7.21 per share, for a total transaction of $1,732,937.92.
• On Tuesday, November 18th, Jan Stahlberg bought 182,882 shares of DiaMedica Therapeutics stock. The stock was bought at an average price of $6.75 per share, with a total value of $1,234,453.50.
• On Monday, November 17th, Jan Stahlberg bought 187,393 shares of DiaMedica Therapeutics stock. The stock was bought at an average cost of $6.52 per share, for a total transaction of $1,221,802.36.

DiaMedica Therapeutics Price Performance

Shares of NASDAQ:DMAC opened at $8.76 on Tuesday. DiaMedica Therapeutics, Inc. has a 12 month low of $3.19 and a 12 month high of $9.23. The firm has a market capitalization of $456.22 million, a P/E ratio of -12.34 and a beta of 1.31. The company’s fifty day moving average price is $7.15 and its 200 day moving average price is $5.73.

DiaMedica Therapeutics (NASDAQ:DMAC) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.02). On average, sell-side analysts anticipate that DiaMedica Therapeutics, Inc. will post -0.59 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. Wall Street Zen cut DiaMedica Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, November 15th. Cowen initiated coverage on shares of DiaMedica Therapeutics in a research note on Thursday, October 30th. They set a “buy” rating for the company. Weiss Ratings restated a “sell (d-)” rating on shares of DiaMedica Therapeutics in a research note on Wednesday, October 8th. HC Wainwright restated a “buy” rating and issued a $12.00 target price on shares of DiaMedica Therapeutics in a report on Friday, August 15th. Finally, TD Cowen assumed coverage on shares of DiaMedica Therapeutics in a report on Thursday, October 30th. They set a “buy” rating for the company. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $12.33.

Institutional Trading of DiaMedica Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Royal Bank of Canada grew its holdings in DiaMedica Therapeutics by 46,879.1% in the 1st quarter. Royal Bank of Canada now owns 155,031 shares of the company’s stock valued at $588,000 after buying an additional 154,701 shares during the period. Goldman Sachs Group Inc. boosted its position in shares of DiaMedica Therapeutics by 76.7% in the first quarter. Goldman Sachs Group Inc. now owns 121,802 shares of the company’s stock worth $462,000 after acquiring an additional 52,854 shares during the last quarter. Jane Street Group LLC grew its holdings in DiaMedica Therapeutics by 138.5% in the first quarter. Jane Street Group LLC now owns 100,669 shares of the company’s stock valued at $382,000 after purchasing an additional 58,457 shares during the period. Perigon Wealth Management LLC acquired a new position in DiaMedica Therapeutics during the second quarter worth approximately $207,000. Finally, World Investment Advisors raised its stake in DiaMedica Therapeutics by 24.7% during the second quarter. World Investment Advisors now owns 31,975 shares of the company’s stock worth $125,000 after purchasing an additional 6,325 shares during the period. 10.12% of the stock is owned by institutional investors and hedge funds.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.